Society of Hematologic Oncology Tenth Annual Meeting 2022

The Society of Hematologic Oncology Tenth Annual Meeting 2022 was designed for a wide range of healthcare professionals interested in hematologic oncology. The target audience included:

• Physicians
• Fellows
• Nurses
• Physician assistants
• Pharmacists
• Students interested in Hematology Oncology, Medical Oncology, and Internal Medicine.

+ Topics:

Additional Agents for R R MM – How Do Will They Fit.ts
Advances in ALL Diagnosis and Treatment – The NOPHO Experience.ts
Advances in the Treatment of NK T Cell Lymphoma.ts
AGILE – A Phase 3, Global, Randomized, Double-Blind Study of Ivo + Aza vs. Placebo + Aza in Newly Diagnosed AML With an IDH1 Mutation.ts
Allogeneic CAR T-Cells in ALL.ts
AML DEBATE- Is MRD More Prognostic Than Initial Presentation Characteristics. CON.ts
AML DEBATE- Is MRD More Prognostic Than Initial Presentation Characteristics. PRO.ts
Amyloidosis – Update and How To Use Novel Agents.ts
Approach to ALL in the Elderly.ts
Approach to Ph-Like ALL.ts
Approaches to and Use of MRD in ALL.ts
Asciminib or Ponatinib for Multiresistant CML Patients.ts
Assessment and Management of TKI-Related AOEs in CML.ts
Basis for Targeting the Microenvironment in Hodgkin Lymphoma.ts
BCL-2 Inhibition in MDS.ts
BCL2i in CLL.ts
Beyond TKI Therapy in CML.ts
Biology and Treatment of LGL Leukemia.ts
Bispecific T-Cell Engagers – Early Data and Where Will We Use Them..ts
Blinatumomab in Pediatric ALL.ts
Camidanlumab Tesirine – Updated Efficacy and Safety in Patients With RR cHL.ts
Can Potential Disease Modifying Agents Change the Indication for Transplant in MPN.ts
CAR T-Cell in MM – When To Use Now, Where Are We Going..ts
CAR T-Cell Therapy in Hodgkin Lymphoma.ts
CAR T-Cells in Indolent B-Cell Lymphomas.ts
Certain Patients With ALL Still Need a Transplant.ts
Challenging Cases in Rare T-Cell Lymphomas.ts
Characteristics of Patients With Myelofibrosis Taking Ruxolitinib for 3 or More Years.ts
Childhood CML.ts
Choosing CAR T-Cell Therapy vs. ASCT in RR Aggressive B-cell Lymphoma.ts
Clinical Significance of B-Cell Receptor Stereotypy in CLL.ts
CLL – Real World Data With Small Molecules.ts
CLL DEBATE- Combination Small Molecules vs. Sequencing in CLL – Pro Combination Small Molecules.ts
CLL DEBATE- How Many Drugs Are Needed in 1L CLL..ts
CNS Prophylaxis in DLBCL.ts
Correlation of TRBC1 by Flow Cytometry With Molecular T-Cell Receptor Clonality for the Investigation of T-Cell Lymphocytosis.ts
Cost-Effectiveness of Polatuzumab Vedotin in Previously Untreated DLBCL.ts
Covalent BTK Inhibitors – How Do They Compare in CLL.ts
Cytopenic Myelofibrosis.ts
DEBATE- Bispecific Antibodies vs. CAR-T for R R MM – Defending Bispecific Antibodies.ts
DEBATE- Bispecific Antibodies vs. CAR-T for R R MM – Pro CAR-T.ts
DEBATE- CAR T-Cell vs. AUTO HCT for RR DLBCL – Pro AUTO HCT.ts
DEBATE- CAR T-Cell vs. AUTO HCT for RR DLBCL – Pro CAR T-Cell.ts
DREAMM-6 Arm-A Interim Analysis – Safety and Clinical Activity of Belantamab Mafodotin With Len + Dex in RR MM.ts
Dual Targeted CAR T-Cells for ALL.ts
Early Intervention in Myelofibrosis.ts
Emerging CAR T-Cell Therapy Approaches in AML.ts
Emerging Treatment Options for MCL.ts
FLT3-Mutated AML – Triplet vs. Doublet Therapy.ts
From Bench to Bedside – A Translational Scientist’s Perspective on How to Transform PTCL Outcome.ts
Future Role of Bispecific Antibodies in the Treatment of Follicular Lymphoma.ts
GLOW Study – First Prospective Data on MRD Outcomes After Fixed-Duration Ibr+Ven vs. Clb+O for 1L Treatment of CLL in Older Adult or Unfit Patients.ts
Has R-CHOP Really Been Replaced as Initial Therapy of DLBCL..ts
How Do We Overcome Resistance to Venetoclax in AML.ts
Immune Therapy Approaches in MDS.ts
Immunotherapeutic Options for Patients With MCL Who Progress on BTK Inhibitors.ts
Immunotherapy – The Way Forward to Maximize TFR in CML..ts
Integrating Novel Agents Into the Management of Cutaneous T-cell Lymphoma.ts
Is it Time to Recognize the Biological Heterogeneity of MCL.ts
Is the Future of AML Therapy All Oral..ts
Is TP53-Mutated AML the Same Disease as TP53-Mutated MDS..ts
Long-Term Outcomes After Haplo-SCT for Hematologic Malignancies.ts
Magrolimab + Azacitidine for Patients With Untreated HR MDS – 5F9005 Phase 1b Study Results.ts
Management of Ph+ ALL in 2022.ts
Management of Prefibrotic Myelofibrosis.ts
Managing the Elderly Patient With Aggressive B-cell Lymphoma in The Modern Era.ts
Menin Inhibitors in AML.ts
MM DEBATE- Auto + Maintenance Should Remain SoC in MM.ts
MM DEBATE- CAR T-Cell Maintenance Will Replace Auto in MM.ts
MM Frontline Therapy for Transplant-Eligible Ineligible Patients- How to Choose Agents.ts
Molecular Classification of MDS.ts
MRD Assessments in MM – Should We. When. Why..ts
New BTKi in CLL.ts
Next Questions CML.ts
Next Questions for MM in the Coming 5-10 Years.ts
Next Questions- ALL.ts
Next Questions- AML.ts
Next Questions- Cellular Therapy.ts
Next Questions- CLL.ts
Next Questions- Follicular Lymphoma.ts
Next Questions- Hodgkin Lymphoma.ts
Next Questions- Mantle Cell Lymphoma.ts
Next Questions- Myelodysplastic Syndromes.ts
Next Questions- Myeloproliferative Neoplasms.ts
Next Questions- T-Cell Lymphoma.ts
Non BCR-ABL Mutations in CML – Do They Matter..ts
Non-Intensive Treatment of Elderly Unfit Patients With AML.ts
Novel Agents in CLL.ts
Novel Chemotherapy Can Eliminate the Need for Transplant in ALL.ts
Novel Therapeutics in Development for Myelofibrosis.ts
Novel Therapies for Eosinophilia.ts
Novel Therapies for ET.ts
Novel Therapies for PV.ts
Novel Treatment Approaches in Relapsed Refractory PTCL.ts
Orca-T Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies.ts
Outcomes of MM Pts Progressing After BCMA-Targeted CAR T-Cell Therapy.ts
PACE and OPTIC Trials – Dose Modification Dynamics of Ponatinib in CP-CML.ts
Phase 1 2 BRUIN Study – Updated Results on Pirtobrutinib in Previously Treated MCL.ts
Phase II Study of Blinatumomab in Combination With Ponatinib in Ph+ ALL – Updated Results.ts
Pivotal Results From a Phase I II Study of Mosunetuzumab Monotherapy for Patients With RR FL Who Have Received ò2 Prior Lines of Therapy.ts
Results from POLARIX, a Phase III Study of Pola-R-CHP vs. R-CHOP Therapy in Patients With Previously Untreated DLBCL.ts
Role of ddPCR in CML Today.ts
Rusfertide Treatment Interruption Reverses Hematological Gains and Upon Reinitiation, Restoration of Clinical Benefit Is Observed in Patients With Polycythemia Vera.ts
Sequencing Agents in Early Relapsed MM.ts
Sequencing BCMA Targeted Agents in MM.ts
Sequencing Novel Agents in Frontline and Second-Line Treatment of Hodgkin Lymphoma.ts
Sequencing Therapy in Indolent Lymphoma – Treatment Choices.ts
State of the Art in CML.ts
Supportive Therapy in CLL.ts
Targeted Approaches in MDS.ts
The Emerging Potential of Bispecific Antibodies as Monotherapy and in Combination for Aggressive B-Cell Lymphoma.ts
The Next Generation of Novel Agents in Development for Aggressive B-Cell Lymphoma.ts
The Next Rational Therapeutic Regimen in Newly Diagnosed PTCL.ts
The Role of Targeted Therapies in Frontline Treatment of MCL.ts
Transplant in MDS.ts
Treating Hodgkin Lymphoma After Brentuximab Vedotin and Anti-PD1 Failure.ts
Treatment of Aggressive B-cell Lymphoma Post-CAR T-Cell Therapy.ts
Update on CD47 Targeting Antibodies.ts
Using Biology to Determine Type and Duration of Treatment in Waldenstrom Macroglobulinemia.ts
What Is the Best Strategy for Therapy-Related AML.ts
What Is the Role of Transplantation for FL in the Era of CAR T-cell Therapy.ts
What’s Next in Aggressive B-Cell Lymphoma.ts